Antibody Information
General Information of This Antibody
| Antibody ID | ANI0RLYZW |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | HuM25 |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Leucine-rich repeat-containing protein 15 (LRRC15) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
HuM25-mcMMAF-E2 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
0.00%
|
Positive LRRC15 expression (LRRC15 +++/++) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-MCMMAF-E2 (12 mg/kg) was demonstrated in PANC-1 xenografts.
|
||||
| In Vivo Model | PANC-1 CDX model | ||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | PANC-1 cells | CVCL_0480 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
8.47% (Day 11)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-MCMMAF-E2 (6 mg/kg) was demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.01 nM - 0.10 nM
|
Positive LRRC15 expression (LRRC15 +++/++) | ||
| Method Description |
Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
|
||||
| In Vitro Model | Colon carcinoma | HCT 116 cells | CVCL_0291 | ||
HuM25-vcMMAE-E2 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
0.00% (Day 28)
|
Moderate LRRC15 expression (LRRC15++; IHC 2+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (12 mg/kg) was demonstrated in MC-38 xenografts.
|
||||
| In Vivo Model | MC-38 CDX model | ||||
| In Vitro Model | Mouse colon adenocarcinoma | MC-38 cells | CVCL_B288 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
59.41% (Day 38)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) was demonstrated in HPAF-II xenografts.
|
||||
| In Vivo Model | HPAF-II CDX model | ||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | HPAF-II cells | CVCL_0313 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
64.94% (Day 23)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (12 mg/kg) was demonstrated in SCC-15 xenografts.
|
||||
| In Vivo Model | SCC-15 CDX model | ||||
| In Vitro Model | Squamous carcinoma | SCC-15 cells | CVCL_1681 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
71.99% (Day 11)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) was demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
80.57% (Day 28)
|
Moderate LRRC15 expression (LRRC15++; IHC 2+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (12 mg/kg) plus anti-PD1 mAb (2 mg/kg) were demonstrated in MC-38 xenografts.
|
||||
| In Vivo Model | MC-38 CDX model | ||||
| In Vitro Model | Mouse colon adenocarcinoma | MC-38 cells | CVCL_B288 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
87.45% (Day 78)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (12 mg/kg) was demonstrated in NW-231 xenografts.
|
||||
| In Vivo Model | PANC-1 CDX model | ||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | PANC-1 cells | CVCL_0480 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
88.36 % (Day 26)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (4.5 mg/kg) was demonstrated in HN-5 xenografts.
|
||||
| In Vivo Model | HPAF-II CDX model | ||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | HPAF-II cells | CVCL_0313 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
88.55% (Day 23)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (12 mg/kg) plus Carboplatin (50 mg/kg) were demonstrated in SCC-15 xenografts.
|
||||
| In Vivo Model | SCC-15 CDX model | ||||
| In Vitro Model | Squamous carcinoma | SCC-15 cells | CVCL_1681 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
89.39% (Day 72)
|
Positive LRRC15 expression (LRRC15 +++/++) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (12 mg/kg) was demonstrated in PANC-1 xenografts.
|
||||
| In Vivo Model | PANC-1 CDX model | ||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | PANC-1 cells | CVCL_0480 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
89.73% (Day 23)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (12 mg/kg) plus Cetuximab (3 mg/kg) were demonstrated in SCC-15 xenografts.
|
||||
| In Vivo Model | SCC-15 CDX model | ||||
| In Vitro Model | Squamous carcinoma | SCC-15 cells | CVCL_1681 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
90.12% (Day 30)
|
Moderate LRRC15 expression (LRRC15++; IHC 2+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (12 mg/kg) was demonstrated in NW-231 xenografts.
|
||||
| In Vivo Model | NW-231 CDX model | ||||
| In Vitro Model | Triple negative breast cancer | NW231 cells | Homo sapiens | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
91.24% (Day 21)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) was demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
91.66% (Day 18)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (3 mg/kg) was demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
91.84% (Day 27)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) was demonstrated in SCC-15 xenografts.
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
91.86% (Day 21)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) was demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
92.25% (Day 23)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (12 mg/kg) plus Radiation (15 Gy) were demonstrated in SCC-15 xenografts.
|
||||
| In Vivo Model | SCC-15 CDX model | ||||
| In Vitro Model | Squamous carcinoma | SCC-15 cells | CVCL_1681 | ||
| Experiment 17 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
92.71% (Day27)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) was demonstrated in NCI-H1650 xenografts.
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 18 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
93.56% (Day 38)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) plus Gemcitabine (80 mg/kg) were demonstrated in HPAF-II xenografts.
|
||||
| In Vivo Model | HPAF-II CDX model | ||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | HPAF-II cells | CVCL_0313 | ||
| Experiment 19 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
96.35% (Day 33)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) was demonstrated in NCI-H1650 xenografts.
|
||||
| In Vivo Model | HN-5 CDX model | ||||
| In Vitro Model | Squamous cell carcinoma | HN-5 cells | CVCL_8128 | ||
| Experiment 20 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
97.05 % (Day 16)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) was demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 21 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
98.10% (Day 21)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) plus Gemcitabine (100 mg/kg) were demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 22 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
98.18% (Day 27)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (6 mg/kg) plus Erlotinib (100 mg/kg) were demonstrated in SCC-15 xenografts.
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 23 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
99.13% (Day 18)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-VCMMAE-E2 (3 mg/kg) plus Docetaxel (7.5 mg/kg) were demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.10 nM
|
Positive LRRC15 expression (LRRC15 +++/++) | ||
| Method Description |
Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
|
||||
| In Vitro Model | Colon carcinoma | HCT 116 cells | CVCL_0291 | ||
HuM25-vcMMAE-DAR4 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
11.00% (Day 26)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-vcMMAE-DAR4 (10 mg/kg) was demonstrated in HCC-827-ER xenografts.
|
||||
| In Vivo Model | HCC-827-ER CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | HCC827 ER1 cells | CVCL_EJ07 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
59.49% (Day 60)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-vcMMAE-DAR4 (3 mg/kg) was demonstrated in SUM190PT xenografts.
|
||||
| In Vivo Model | SUM190PT CDX model | ||||
| In Vitro Model | Breast inflammatory carcinoma | SUM190PT cells | CVCL_3423 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
84.03% (Day 21)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huM25-vcMMAE-DAR4 (3 mg/kg) was demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.